title: Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits.
abstract: BACKGROUND
  Fibrates are peroxisome proliferator-activated receptor alpha (PPARalpha) agonists which modulate many aspects of lipoprotein metabolism and inflammation. They have been recently demonstrated to inhibit in vitro expression of tissue factor (TF), the main initiator of blood coagulation, which probably plays a pivotal role in thrombotic complications after plaque rupture. We investigated whether a 4-week fenofibrate treatment might affect the TF expression and cellular modifications in angioplasty-induced rabbit plaque rupture.
  
  
  METHODS
  After plaque rupture by balloon angioplasty in atheromatous rabbits, animals were randomized in an untreated group or a group receiving fenofibrate. The TF content of arterial wall and the histological modifications were analyzed after 4 weeks.
  
  
  RESULTS
  Fenofibrate decreased in vivo TF expression (-42%, P<.05) and plaque cholesterol content (P<.01) in iliac arteries. Fenofibrate significantly improved the reendothelialization process by 51% (P<.05) and modified cellular distribution in the plaque toward increased stabilization.
  
  
  CONCLUSIONS
  These data indicate that the PPARalpha-activator fenofibrate reduces plaque thrombogenicity and accelerates endothelial regrowth which, altogether, might improve plaque stability. These effects may underlie the preventive effects of fibrate therapy in atherosclerosis complications.
authors.affiliation: Inserm, ERI-9, Lille, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Jeanpierre
authors.forename: Thierry
authors.initials: T
authors.lastname: Le Tourneau
authors.forename: Christophe
authors.initials: C
authors.lastname: Zawadzki
authors.forename: Eric
authors.initials: E
authors.lastname: Van Belle
authors.forename: Frederic
authors.initials: F
authors.lastname: Mouquet
authors.forename: Sophie
authors.initials: S
authors.lastname: Susen
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ezekowitz
authors.forename: Bart
authors.initials: B
authors.lastname: Staels
authors.forename: Brigitte
authors.initials: B
authors.lastname: Jude
authors.forename: Delphine
authors.initials: D
authors.lastname: Corseaux
mesh_terms: D000800:Angioplasty, Balloon / Q000009:adverse effects; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001835:Body Weight / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002791:Cholesterol, Dietary / Q000097:blood; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D011345:Fenofibrate / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007083:Iliac Artery / Q000187:drug effects* / Q000293:injuries / Q000378:metabolism / Q000473:pathology; D008297:Male; D047493:PPAR alpha / Q000819:agonists / Q000378:metabolism; D011817:Rabbits; D012421:Rupture; D013925:Thromboplastin / Q000378:metabolism; D013927:Thrombosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D002791:Cholesterol, Dietary; D000960:Hypolipidemic Agents; D047493:PPAR alpha; D013925:Thromboplastin; D011345:Fenofibrate